XPENG-INC.
29.10.2020 13:02:09 CET | Business Wire | Press release
XPeng Inc. (“XPeng” or the “Company”, NYSE: XPEV), a leading Chinese smart electric vehicle (“Smart EV”) company, this week released its 2nd Smart Car Operations Report, following its 2nd annual Tech Day where the company unveiled its newly developed cutting edge autonomous driving and in-car smart features.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005643/en/
“2020 to 2022 is a period of gaining significant momentum for the Smart EV sector which will rapidly accelerate from 2023 to 2025 and a create massive disruption to traditional ICE vehicles,” said He Xiaopeng, Chairman & CEO of XPeng.
“End-to-end R&D, data-driven capabilities and fast growth are three initiatives needed for a company to gain long-term competitive advantages and dominant market share,” Chairman He added.
At its 2nd Tech Day, XPeng launched 18 firmware OTA updates, adding 82 new features to its vehicles. The voice assistant’s average monthly utilization rate reached 99.74% and in-car navigation utilization rate achieved 92.54%, according to XPeng’s 2020 Smart Car Operations Report.
XPeng’s autonomous driving system XPILOT 3.0, planned for release in the first quarter of 2021, will provide Navigation Guided Pilot (NGP) for highways and memory auto parking for carparks. These new features address some of the major challenges for drivers in China.
Navigation Guided Pilot (NGP)
Built on XPILOT 3.0, the NGP highway solution enables autonomous driving from point A to point B. The solution will be available on all of China’s major highways with high-precision digital maps and will be the most advanced navigation guided autonomous driving system for production models in China.
The NGP system incorporates driving scenarios specific to China such as traffic cone recognition and avoidance, large truck avoidance, night overtaking reminders, faulty vehicle avoidance, and vehicle follow on congested roads. It can also handle adverse weather conditions, complex roads and locations without GPS signals.
The solution will be the only 360° dual-perception system in the industry with optimal identification of automobile surroundings with the most powerful positioning capabilities in production.
Memory Auto Parking
The XPILOT 3.0 will feature a Memory Parking functionality for parking lots. This feature will recognize side-front parking spaces and cover “the last mile” of parking with the ability to avoid obstacles, plan routes and park with extreme precision. The feature is the world's first auto parking system for production vehicles that does not require any car park modifications.
“Our core competitive advantage is our end-to-end in-house developed software for autonomous driving. In the past few years, we have developed a full range of self-developed R&D and implemented these advanced technologies into our models. There are only two auto makers in the world that have end-to-end autonomous driving capabilities and XPeng is one of them,” said XinZhou Wu, Vice President of Autonomous Driving at XPeng.
World’s first All Voice In-car System
XPeng also introduced another update of its Xmart OS operating system with the world’s first All Voice In-car System, able to deliver the majority of in-car functions. The updated system is the world’s first in-car voice system that responds to continuous driver-vehicle dialogues and is able to execute 10 voice commands every 25 seconds.
“Driver-vehicle interaction technology has evolved from physical buttons to touch screens, to today’s voice commands,” said Ji YU, Vice President of Internet at XPeng.
Xmart OS is now the world’s first open-end vehicle hardware system which allows third-party applications to access vehicle status and data to produce tailor-made infotainment. It also has a unique programmable smart lighting system where users can personalize its lighting effects in the future.
Smart Car by Numbers - 2020 Xpeng Operations Report*
XPeng’s 2nd annual Smart Car Operations Report is based on data from XPeng vehicles from Jan 1, 2020 to Sep 30, 2020. The report illustrates the Smart Cars’ most appealing aspects and how customers value smart features.
- Firmware OTA launched - 18 times in the past 20 months
- New features added - 82 items
- Voice assistant monthly average utilization rate - 99.74%
- In-car navigation utilization rate - 92.54%
Intelligence Makes Driving Easier
Driving range
- Longest distance driven by a single vehicle - 3,784 km
- Accumulative monthly mileage driven by all users - 30,300,000 km
Auto Parking
- Average monthly obstacle avoidance - 9,585 times
- Average monthly auto parking - 88,000 times
- Average time taken for auto parking - 32.3 seconds
ACC (Adaptive Cruise Control)
- Utilization rate/month – 65.59%
- Average distance driven/month – 2,286,000 km
- Distance driven/car/day – 24.6 km
LCC (Lane Centering Control)
- Utilization rate/month – 42.48%
- Distance driven/month – 1,127,000 km
- Distance driven/car/day – 21.7 km
Intelligence Makes Interaction Easier
- Voice Assistant “Xiao P” total activation - 17,910,000 times
- Intelligent recommendations provided - 4,484,000 items
- Intelligent navigation routes recommended by voice assistant - 19,170,000 routes
* Data provided by Xpeng Lab based on data from all Xpeng vehicles from 1 January 2020 to 31 September 2020.
About XPeng
XPeng Inc. is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers in China. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPeng develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrification/electronic architecture. XPeng is headquartered in Guangzhou, China, with offices in Beijing, Shanghai, Silicon Valley, and San Diego. The Company’s Smart EVs are manufactured at plants in Zhaoqing and Zhengzhou, located in Guangdong and Henan provinces, respectively. For more information, please visit https://en.xiaopeng.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005643/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
